Quantitate biotherapeutic drug-targets through Pharmacokinetic & pharmacodynamic

Nov. 28, 2012 - PRLog -- This year’s event will feature a wide variety of speakers and presentations, offering delegates the perfect opportunity to discuss new opportunities and strategies to accelerate go/no-go decision making in early and clinical development.

SMi is pleased to confirm Andrew Warren, Director, PK/PD/Immunogenicity Bioanalysis, Novartis as a speaker of the event.

He will discuss how to deliver safe starting and therapeutically relevant escalation doses for human studies, as well as target-mediated drug disposition and Assaying captured drug-target complexes

Attending will enable delegates to:

Accelerate companion diagnostics development for therapeutic indications

Validate and deliver biomarkers for patient selection during clinical trials

Implement sub-grouping in patient segmentation studies

Utilise revised FDA regulatory guidelines to aid product development

Optimise reimbursement strategies for diagnostics

Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit63.asp alternatively contact Cem Tuna on +44 0 207 827 6736 or email on ctuna@smi-online.co.uk